When Does a Patient Need an Endocrinologist?

The question behind the slogan

Two claims are often made in the same breath: that gender-dysphoria care requires specialised training most physicians do not have, and that patients cannot find clinicians willing to provide it. Both may be true for particular services in particular places. Neither is true of "the care" as a whole, because the phrase covers activities as different as treating an unrelated infection, diagnosing a psychiatric condition, managing an adult's long-established hormone regimen, deciding whether an adolescent should begin puberty suppression, and performing surgery. Inference

Clinically precise language helps. The American Psychiatric Association distinguishes transgender identity, which "is not a psychiatric diagnosis," from gender dysphoria, a diagnosis concerned with clinically significant distress. Documented C08 Competence attaches to tasks performed for a diagnosis, not to the identity of a patient. This article maps the tasks, the expertise the principal guideline assigns to each, and the measurements that would show whether patients can actually reach them.

What the guideline says about expertise

The Endocrine Society's clinical practice guideline (Hembree et al., 2017) remains its operative guideline; the Society's guidelines-in-development page, updated July 17, 2026, lists "Gender-Affirming Care" as "in development," described as an update to the 2017 guideline, with no publication date. Documented C01C02 Three of its statements about expertise matter here.

• For adults: "the treating clinicians (collectively) should have expertise in transgender-specific diagnostic criteria, mental health, primary care, hormone treatment, and surgery." Documented C01
• For adolescents: "For the care of youths during puberty and older adolescents, an expert multi-disciplinary team comprised of medical professionals and mental health professionals should manage treatment." Documented C01
• For diagnosis in adults (Recommendation 1.1): "only trained mental health professionals (MHPs) who meet the following criteria should diagnose gender dysphoria (GD)/gender incongruence in adults." Documented C01

The word "collectively" carries the argument. The guideline describes the expertise a team should hold among its members; it does not say that each prescriber must personally possess every competence, and it does not say that the prescriber must be an endocrinologist. Inference Conversely, it does not say that any physician may prescribe without the relevant expertise. It describes a distributed model: diagnosis by qualified mental-health professionals, hormone management by clinicians with hormone-treatment expertise, primary care by primary-care clinicians, and surgery by surgeons — coordinated.

Competence, task by task

The table shows why categorical claims fail. A primary-care physician who has no training in initiating adolescent puberty suppression is not qualified to provide it, and §125.6(b)(2) states that California's licensee-discrimination statute does not require the physician to try. Proved C09 The same physician is fully qualified to treat the same patient's asthma, and no qualification argument reaches that care. Between these poles lie the tasks — adult hormone continuation, laboratory monitoring, recognition of adverse effects — where competence is acquirable and where the real policy question is whether training and consultation are available. Inference

Where primary care fits

The evidence on primary-care participation is thin but not empty. In the serial survey of military family physicians, willingness to prescribe adult hormones independently or with help rose from 47% in 2016 to 62% in 2023, while the share reporting no relevant training fell from 74% to 44%; willingness was associated with four or more hours of education (odds ratio 2.2). Proved C03C04 In the single-centre academic survey, objection to prescribing for adults (23.5%) was lower than objection for minors (33.0%), and objection to general care was almost absent. Proved C05

Read together, these studies suggest that adult hormone management is a task many generalists regard as within reach with modest training and support, and that adolescent treatment is regarded by more clinicians as outside their scope. Inference That is broadly the division the guideline itself draws. It implies a practical model: primary-care clinicians providing ordinary care to every patient, some primary-care clinicians trained to continue and monitor adult regimens with consultation available, mental-health professionals providing assessment, and multidisciplinary teams — typically in academic or specialty centres — providing adolescent care. An endocrinologist is most clearly needed where the adolescent guideline requires a multidisciplinary team, where a patient has coexisting endocrine disease, or where monitoring reveals complications beyond a generalist's competence. Inference

The model has a cost that the slogans conceal. Every handoff between tiers is a point at which care can fail: a referral not accepted, a result not returned, a patient lost between clinics. Those are the same failure points examined in Beyond the billable visit. A distributed model is only as good as its handoffs.

Adolescents: a different service

The adolescent setting differs on every axis: consent and assent, developmental considerations, the evidence base, and — since October 13, 2026 — the payment pathway for Medi-Cal members. Executive-branch and commissioned evidence reviews have characterised the evidence for adolescent interventions as weak. HHS's review states that "the overall quality of evidence concerning the effects of any intervention on psychological outcomes, quality of life, regret, or long-term health, is very low," while describing itself as "not a clinical practice guideline." Documented C11 A University of York systematic review commissioned for England's Cass Review concluded that "There is a lack of high-quality research assessing puberty suppression in adolescents experiencing gender dysphoria/incongruence." Documented C12 The Endocrine Society's update to its 2017 guideline remains in development. Documented C02 The evidence dispute, including published critiques of those reviews, is examined in October 13 and after.

For the competence question, the consequence is straightforward. Adolescent interventions are, on any reading of the guideline, specialist multidisciplinary services; a generalist's declining to initiate them is a recognition of scope, not a refusal of a patient. The generalist's continuing duties — ordinary care, honest information, help reaching the appropriate service, and continuity of everything else — remain. Inference C10

The accepting-clinician problem

Access depends less on how many clinicians are competent in principle than on how many are accepting new patients, for a given service, under a given payer, within a reachable distance, in a clinically appropriate time. No published, representative California count of such clinicians, by service, age group and payer, was located for this article. Open That absence is the central fact of the accepting-clinician problem: the shortage is asserted on all sides, and measured by no one in the form that would allow it to be addressed.

The October 13 federal funding change has made the measurement problem harder and more urgent. For Medi-Cal members under 18 and CHIP members under 19, HCAI now administers "a grant program" providing "state-only funding" for puberty blockers, hormones and surgery for gender dysphoria, while office visits, laboratory work, speech therapy and psychotherapy remain with Medi-Cal; new prescriptions are routed through an HCAI pharmacy arrangement. Documented C06 A clinician who accepts Medi-Cal is not, by that fact, enrolled in or familiar with the state-only route. A patient-facing directory that lists a clinician as accepting Medi-Cal therefore says nothing about whether the clinician can be paid for the service the patient needs. Inference

Continuity when services disappear

Continuity is the least discussed and most practical part of this controversy. Services can disappear for reasons unrelated to any clinician's conscience: a clinic closes, a programme loses funding, a clinician moves, a payer changes its rules, a patient crosses a state line. The October 13 change is a concrete example. The federal rule permits federal funding for "cross-sex hormone therapy for a tapering period of up to 6 months from October 13, 2026" — the rule's term — and HCAI states that members already on hormones as of that date "will continue to have these medications reimbursed by Medi-Cal through April 12, 2027," adding that "This transition period does not apply to puberty blockers or surgical interventions." Documented C07C06

Whatever one's view of the underlying policy, an abrupt interruption of an established hormone regimen raises clinical questions of its own, and a patient whose prescriber leaves or whose payment route changes needs a planned transition, not a gap. Inference The AMA's ethics opinion frames the individual clinician's floor: continue other ongoing care or formally terminate the relationship, and in general refer for treatment the physician declines to offer. Documented C10 At the system level, continuity requires something no individual clinician can supply: a current map of who accepts whom, for what, under which payment route. The site's broader explainer on LGBTQ+ health access amid changing federal rules addresses the federal rule changes; the measurement gap remains.

What should be measured

1. Accepting clinicians by service. Counts of clinicians accepting new patients for adult hormone initiation, adult continuation, adolescent multidisciplinary assessment, and surgery — separately.
2. By payer and route. Medi-Cal, the HCAI state-only route, Medicare, commercial coverage and self-pay, because acceptance under one is not acceptance under another.
3. Time and distance. Days from request to accepted appointment and travel distance, by region.
4. Consultation capacity. Availability of specialist consultation to generalists who continue adult regimens.
5. Transition outcomes. For patients affected by the October 13 change, whether regimens were continued, tapered by clinical decision, or interrupted without a plan.
6. Training supply. Availability and uptake of task-specific education for clinicians who wish to provide particular services.

Until those measures exist, claims about a shortage should be stated as hypotheses, and claims that the system is absorbing individual limitations should be stated as hypotheses too. For the legal framework governing individual limitations, see Physician competence, religious conscience and equal access; for what the attitude surveys do and do not show, see the surveys.

Correction history

Sources

Official issuers, statutes, opinions and original studies are preferred; reproductions of primary legal text are identified. Checked 1 November 2026 unless stated. A source that opens is not proof of every neighbouring claim.

1. C01Endocrine Society — Gender Dysphoria/Gender Incongruence guideline resourcesProfessional guideline (Hembree et al., JCEM, September 2017) · resource page dated 25 Oct 2024
2. C02Endocrine Society — Guidelines in developmentLists “Gender-Affirming Care” as in development, an update to the 2017 guideline · page updated 17 Jul 2026 · no publication date given
3. C03Domalaon et al., J Prim Care Community Health 2024Military family physicians, 2016 (n=180) and 2023 (n=386)
4. C04Domalaon et al. — full text (PMC11320690)Training, willingness and education association
5. C05Patel et al., Journal of Appalachian Health 2024Single-centre survey, n=115, 2018 data
6. C06HCAI — Gender Affirming Care Services for Youth: What Providers Need to KnowCalifornia state agency · metadata modified 20 Oct 2026
7. C07CMS-2451-F, 91 FR 52406 (13 Aug 2026)Final rule · effective 13 Oct 2026
8. C08American Psychiatric Association — Gender DysphoriaTerminology
9. C09Cal. Bus. & Prof. Code §125.6 (reproduction)Statute · qualification limitation (b)(2)
10. C10AMA Code of Medical Ethics, Opinion 1.1.7Ethics opinion · continuity and referral duties
11. C11HHS — Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best PracticesExecutive-branch evidence review · released 1 May 2025; peer-reviewed version dated 19 Nov 2025
12. C12Taylor J, et al. Puberty suppression in adolescents experiencing gender dysphoria/incongruence: a systematic review. Arch Dis Child 2024University of York systematic review commissioned for the Cass Review · doi:10.1136/archdischild-2023-326669

Reviewed and approved for publication by Kanwar Partap Singh Gill, MD. Healthcare Controversies examines disputes about medical care, institutions, money, conscience and law using public records. It is institutional and legal analysis: not patient-specific clinical guidance, not legal advice, and not a finding about any named clinician or organisation beyond what the cited records establish. Survey figures are reported with their denominators and dates; a funding rule, guideline, audit sample or payment incentive is not treated as proof of more than it measures.

Healthcare Controversies · opening investigations

1. 01 · Gender-dysphoria care · California lawCompetence, conscience and equal access
2. 02 · Denominators, reasons, limitsWhat the physician-objection surveys show
3. 03 · Competence by task · accessWhen does a patient need an endocrinologist?
4. 04 · CMS-2451-F · HCAI · litigationThe October 13 federal funding rule and California's response
5. 05 · Fresno · independent-practice economicsHalf a county on Medi-Cal
6. 06 · Fresno · Kings · MaderaCalViva's 2025 access survey
7. 07 · FQHC payment · completion of careBeyond the billable visit
8. 08 · Private equity · MSOs · CPOMClinical independence after SB 351
9. 09 · AI notes, orders and responsibilitySigned but not written

All fifteen categories and 150 topics · Licensure, NPI and certification (physician-authority series) · Policy library · Editorial standards